Laura Sepp-Lorenzino - 30 Aug 2021 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role: EVP, Chief Scientific Officer
Signature: /s/James Basta, attorney-in-fact
Issuer symbol: NTLA
Transactions as of: 30 Aug 2021
Net transactions value: -$13,658,754
Form type: 4
Filing time: 01 Sep 2021, 19:34:46 UTC
Previous filing: 06 Aug 2021
Next filing: 03 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NTLA	Common Stock	Options Exercise	$361,800	+27,000	+1129%	$13.40	29,391	30 Aug 2021	Direct
transaction	NTLA	Common Stock	Options Exercise	$997,500	+70,000	+238%	$14.25	99,391	30 Aug 2021	Direct
transaction	NTLA	Common Stock	Sale	$2,419,407	-15,839	-16%	$152.75	83,552	30 Aug 2021	Direct	F1, F2
transaction	NTLA	Common Stock	Sale	$3,171,898	-20,645	-25%	$153.64	62,907	30 Aug 2021	Direct	F1, F3
transaction	NTLA	Common Stock	Sale	$4,437,101	-28,669	-46%	$154.77	34,238	30 Aug 2021	Direct	F1, F4
transaction	NTLA	Common Stock	Sale	$2,507,655	-16,115	-47%	$155.61	18,123	30 Aug 2021	Direct	F1, F5
transaction	NTLA	Common Stock	Sale	$1,164,166	-7,425	-41%	$156.79	10,698	30 Aug 2021	Direct	F1, F6
transaction	NTLA	Common Stock	Sale	$620,352	-3,932	-37%	$157.77	6,766	30 Aug 2021	Direct	F1, F7
transaction	NTLA	Common Stock	Sale	$240,734	-1,515	-22%	$158.90	5,251	30 Aug 2021	Direct	F1, F8
transaction	NTLA	Common Stock	Sale	$423,525	-2,653	-51%	$159.64	2,598	30 Aug 2021	Direct	F1, F9
transaction	NTLA	Common Stock	Sale	$33,217	-207	-8%	$160.47	2,391	30 Aug 2021	Direct	F1, F10

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NTLA	Stock Option (right to buy)	Options Exercise	$0	-27,000	-25%	$0.000000	82,000	30 Aug 2021	Common Stock	27,000	$13.40	Direct	F11
transaction	NTLA	Stock Option (right to buy)	Options Exercise	$0	-70,000	-47%	$0.000000	80,000	30 Aug 2021	Common Stock	70,000	$14.25	Direct	F12

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.16 to $153.155, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.16 to $154.15, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.22 to $155.215, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
F5	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.22 to $156.19, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
F6	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.22 to $157.21, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
F7	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.305 to $158.245, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
F8	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.31 to $159.165, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
F9	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.31 to $160.17, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
F10	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.40 to $160.53, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
F11	The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 53,437 shares as of August 30, 2021.
F12	The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 84,375 shares as of August 30, 2021.